Apriori Bio, a Flagship Pioneering company focused on developing prospective, variant-resilient vaccines, and the Agency for Science, Technology and Research Infectious Diseases Labs (A*STAR IDL) announced a strategic research partnership to co-develop and evaluate next generation self-amplifying RNA (saRNA) vaccines targeting seasonal and pandemic influenza.